Treatment of Prolonged Grief Disorder in Combat Veterans
NCT ID: NCT02283333
Last Updated: 2021-02-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
155 participants
INTERVENTIONAL
2014-12-01
2020-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will enroll 140 Veterans, aged 21 years and older, who served in any combat era. All Veterans will meet criteria for PGD. There will be assessments at baseline, 1 week, 3 months, and 6 months post treatment. During the treatment phase, Veterans will undergo 7 weekly sessions of either BATE-G or standard treatment. Sessions 2-6 will be delivered via televideo to the Veteran's home.
We hypothesize that BATE-G will be more effective than standard treatment in reducing symptoms of PGD, both at post-treatment and follow-up. Moreover, BATE-G will be more effective in reducing acute emotional distress and preventing long-term emotional distress in terms of general depression and anxiety symptoms. BATE-G will result in increased frequency of completed positively reinforcing, community-based events when compared to Cognitive Restructuring and Supportive Grief Counseling. BATE-G will also result in greater improvements in perceived social support and health.
Note: This project is the first evidence-based treatment for PGD in military populations, thus addressing a significant service gap.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prolonged Grief and Suicide Among Veterans
NCT01247025
Group Treatment for PTSD: A Randomized Clinical Trial With Veterans
NCT01544088
Brief Cognitive Behavioral Treatment of Deployment-Related PTSD Symptoms in Primary Care Settings
NCT02290639
Treatment of Depression in Patients With PTSD
NCT00013091
Brief Treatment for Posttraumatic Stress Disorder
NCT03033602
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BATE-G
Behavioral Activation and Therapeutic Exposure - Grief therapy are delivered in 7 weekly sessions to the participant.
BATE-G
Behavioral Activation and Therapeutic Exposure - Grief therapy is delivered in 7 weekly sessions to the participant.
Standard Treatment
Cognitive Restructuring and Supportive Grief Counseling are delivered in 7 weekly sessions to the participant.
Standard Treatment
Cognitive Restructuring and Supportive Grief Counseling is delivered in 7 weekly sessions to the participant.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BATE-G
Behavioral Activation and Therapeutic Exposure - Grief therapy is delivered in 7 weekly sessions to the participant.
Standard Treatment
Cognitive Restructuring and Supportive Grief Counseling is delivered in 7 weekly sessions to the participant.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants may be male or female,
* age 21 and above,
* with a diagnosis of Prolonged Grief Disorder.
* Veterans starting a new psychotropic medication at baseline will be asked to wait 4 weeks for medication stabilization before starting the study.
Exclusion Criteria
* Individuals with both suicidal ideation and clear intent,
* Individuals with homicidal ideation and or intent,
* Individuals meeting criteria for substance dependence,
* Individuals who cannot or are unwilling to schedule regular weekly appointments (with the exception of Veterans who have medical and/or transportation barriers,
* Individuals who are already enrolled in another trial for PTSD and/or depression will be excluded.
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VA Office of Research and Development
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ron E. Acierno, PhD MS BA
Role: PRINCIPAL_INVESTIGATOR
Ralph H. Johnson VA Medical Center, Charleston, SC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ralph H. Johnson VA Medical Center, Charleston, SC
Charleston, South Carolina, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CX001102
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
CLNA-001-14S
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.